Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-03-14 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
东莞证券关于特一药业2021年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the 2021 annual fundraising funds deposit and usage of Te Yi Pharmaceutical Group Co., Ltd. It references regulatory approvals, specific fundraising events (2017 convertible bonds and 2021 private placement), detailed usage and balance tables, and audit opinions from accounting firms. The document is focused on the verification and audit of fundraising funds usage and compliance with relevant securities regulations. It is not a full annual report or earnings release but a specialized audit/verification report on fundraising funds usage. The presence of audit opinions and detailed fund usage aligns with the definition of an Audit Report / Information (AR). The document length (10,389 characters) and content confirm it is the report itself, not just an announcement. Therefore, the correct classification is AR with high confidence. FY 2021
2022-03-14 Chinese
年度募集资金使用情况专项说明
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the actual storage and use of raised funds for the year 2021 by 特一药业集团股份有限公司. It details the amounts raised through convertible bonds and non-public stock issuance, the use of these funds, the storage in special accounts, and compliance with regulatory guidelines from the Shenzhen Stock Exchange. The document includes detailed tables of fund usage, storage, and management, as well as audit verification references. This type of report is a specialized disclosure on the use of capital raised by the company, which fits the category of Capital/Financing Update (CAP) as it relates to fundraising and capital usage updates. It is not a full annual report, audit report, or earnings release, but a focused report on capital raising and fund usage. The document length is over 10,000 characters and contains substantive financial data and analysis related to capital usage, supporting the CAP classification with high confidence.
2022-03-14 Chinese
内部控制鉴证报告
Regulatory Filings
2022-03-14 Chinese
2021年年度审计报告
Regulatory Filings
2022-03-14 Chinese
2021年度独立董事述职报告（李桂生）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2021 by a specific independent director of the company. It details the director's attendance at board and shareholder meetings, independent opinions on various company matters, committee work, investigations, and efforts to protect shareholder rights. The content is a narrative report on the director's activities and opinions during the year, not a financial report or an announcement. It is not an Annual Report (10-K), Audit Report, or any other financial filing. It is a management-related report focusing on board activities and governance oversight by an independent director. Therefore, the document fits best under Board/Management Information (MANG). The document length is 3300 characters, which is relatively short but contains substantive content about board and management activities, not just an announcement or certification. Hence, it is not RPA or RNS.
2022-03-14 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2021 by an independent director of the company. It details the director's attendance at board and shareholder meetings, independent opinions on various company matters, committee work, investigations, and efforts to protect shareholder rights. It is a narrative report on the director's duties and observations rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. This type of document fits best under Board/Management Information (MANG) as it relates to board member activities and governance oversight by an independent director.
2022-03-14 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.